A unique poikilodermatous condition associated with a de novo heterozygous ATR missense variant

Clicks: 2
ID: 317591
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #54 of 171 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 171 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
We describe a child with progressive poikiloderma telangiectases, and punctate palmoplantar keratoses. Whole genome sequencing identified a de novo heterozygous missense variant in the ATR (Ataxia Telangiectasia and Rad3-related) gene (c.3982G>A, p.Val1328Ile). Phenotypic appearances are in keeping with the sole published pedigree with a heterozygous ATR variant (p.Gln2144Arg), with 24 affected members across 5 generations having telangiectases, eyebrow and hair loss, and thin dental enamel. This pedigree has a strong associated with early-onset oropharyngeal cancer and pulmonary fibrosis, for which our patient remains under close surveillance.
Reference Key
openalex_W7164907364 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lauren Passby, Gabriela Petrof, Malobi Ogboli, Gavin Ryan, Grant S Stewart, Celia Moss, Marie‐Louise Lovgren
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag238
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.